Collegium Pharmaceutical, Inc.
General ticker "COLL" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.0B (TTM average)
Collegium Pharmaceutical, Inc. follows the US Stock Market performance with the rate: 51.6%.
Estimated limits based on current volatility of 2.5%: low 38.57$, high 40.69$
Factors to consider:
- Total employees count: 357 (+81.2%) as of 2024
- Top business risk factors: Dependence on successful product commercialization, Liquidity and credit risks, Operational and conduct risks, Product commercialization failure, Supply chain disruptions
- Current price 18.8% above estimated high
- Earnings for 12 months up through Q4 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [19.99$, 33.35$]
- 2025-12-31 to 2026-12-31 estimated range: [18.65$, 31.37$]
Financial Metrics affecting the COLL estimates:
- Positive: with PPE of 4.6 at the end of fiscal year the price was neutral
- Positive: Operating cash flow per share per price, % of 21.52 > 12.96
- Positive: Operating profit margin, % of 26.91 > 18.38
- Negative: Shareholder equity ratio, % of 13.76 <= 19.40
- Negative: Investing cash flow per share per price, % of -30.21 <= -14.22
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 3.99
- Negative: negative Industry operating cash flow (median)
- Negative: 0 < Inventory ratio change, % of 0.09
Short-term COLL quotes
Long-term COLL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $566.77MM | $631.45MM | $780.57MM |
| Operating Expenses | $399.81MM | $461.55MM | $600.93MM |
| Operating Income | $166.96MM | $169.90MM | $179.64MM |
| Non-Operating Income | $-91.23MM | $-71.33MM | $-87.02MM |
| Interest Expense | $83.34MM | $73.97MM | $82.31MM |
| Income(Loss) | $75.73MM | $98.57MM | $92.62MM |
| Taxes | $27.58MM | $29.38MM | $29.75MM |
| Profit(Loss)* | $48.16MM | $69.19MM | $62.87MM |
| Stockholders Equity | $195.43MM | $228.84MM | $301.68MM |
| Inventory | $32.33MM | $35.56MM | $40.91MM |
| Assets | $1,143.31MM | $1,663.59MM | $1,656.83MM |
| Operating Cash Flow | $274.75MM | $204.98MM | $329.32MM |
| Capital expenditure | $0.46MM | $1.65MM | $1.74MM |
| Investing Cash Flow | $-70.81MM | $-287.76MM | $-63.53MM |
| Financing Cash Flow | $-140.18MM | $-60.60MM | $-110.25MM |
| Earnings Per Share** | $1.43 | $2.14 | $1.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.